GYRE THERAPEUTICS INC (GYRE:NASDAQ)
$7.87 -0.07 (-0.8816%)
Analysed GYRE THERAPEUTICS INC (GYRE:NASDAQ) News Sources
Exploring Three High Growth Tech Stocks In The US Market
27-03-2026
yahoo.com
Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
17-03-2026
yahoo.com
Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss Estimates
12-03-2026
yahoo.com
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
12-03-2026
yahoo.com
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
09-03-2026
yahoo.com
Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction
03-03-2026
yahoo.com
Sector Update: Health Care Stocks Retreat Late Afternoon
02-03-2026
yahoo.com
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline
02-03-2026
yahoo.com
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
25-02-2026
yahoo.com
High Growth Tech Stocks in US for February 2026
11-02-2026
yahoo.com
What is the current price of GYRE THERAPEUTICS INC (GYRE:NASDAQ)?
The current price of GYRE THERAPEUTICS INC (GYRE:NASDAQ) is $7.87.
GYRE THERAPEUTICS INC (GYRE:NASDAQ) absolute price change since previous trading day?
The absolute price change of GYRE THERAPEUTICS INC (GYRE:NASDAQ) since the previous trading day is $-0.07.
GYRE THERAPEUTICS INC (GYRE:NASDAQ) percentage price change since previous trading day?
The percentage price change of GYRE THERAPEUTICS INC (GYRE:NASDAQ) since the previous trading day is -0.8816%.
What is the most recent average sentiment score for GYRE THERAPEUTICS INC (GYRE:NASDAQ)?
The most recent average sentiment score for GYRE THERAPEUTICS INC (GYRE:NASDAQ) is 74 out of 100.
What is the most recent average sentiment for GYRE THERAPEUTICS INC (GYRE:NASDAQ)?
The most recent sentiment for GYRE THERAPEUTICS INC (GYRE:NASDAQ) is .
SEC-8K** Filing Available For GYRE THERAPEUTICS INC (GYRE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.